SAN FRANCISCO, April 26 /PRNewswire/ -- XDx, a molecular diagnostics company, today announced its AlloMap(R) molecular expression test will be the subject of presentations and discussions at the 27th Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation (ISHLT) at the Hilton San Francisco.
Data presented at the ISHLT sessions demonstrates that AlloMap testing may help reduce immunosuppression without the need for invasive biopsies and may allow for prediction of future occurrence of cardiac allograft rejection.
“The data being presented point to the potential clinical utility of molecular expression testing in monitoring rejection based on gene-expression profiling,” said Mario C. Deng, M.D., director of Cardiac Transplantation Research, Columbia University Medical Center/New York Presbyterian Hospital, and co-principal investigator in the Cardiac Allograft Gene Expression Observational (CARGO) study. “The fact that we can accomplish this non- invasively, without requiring a routine biopsy, is likely to impact the care and quality of life of many patients who have undergone heart transplantation.”
In separate studies, recent data from the Lung Allograft Rejection Gene expression Observation (LARGO) study provides the first confirmation that a non-invasive blood test can detect organ rejection in lung transplant patients.
More information on ISHLT can be found at http://www.ishlt.org .
About XDx
XDx’s mission is to improve patient care by developing molecular diagnostics that translate an individual’s immune status into clinically actionable information. Founded in 2000, XDx is a molecular diagnostics company that utilizes state-of-the-art genomic technology and sophisticated bioinformatics analyses to understand and measure the immune processes that underlie specific immune-mediated conditions. Physicians can use this information to optimize patient treatment and minimize the long-term consequences of immunosuppressive therapies.
XDx’s science and technology is now being evaluated in patients with solid organ transplants. Building on the discoveries made during the development of AlloMap testing for heart transplant patients, which included the identification of many genes and pathways involved in tissue rejection, XDx is now developing a product for use by physicians to better manage lung transplant patients. Beyond the use of AlloMap testing in assessing immune response in solid organ transplantation, XDx scientists are applying similar approaches to create new molecular diagnostic tests for the improved clinical management of immune-mediated inflammatory diseases, such as systemic lupus erythematosus (SLE or lupus,) to diagnose and predict clinical flares common in a variety of these diseases.
In addition to its potential for use by physicians for better patient management, the XDx approach is of interest to pharmaceutical companies looking to use biomarkers predictive of drug efficacy in order to proactively identify patient response and to better target their drug development efforts and clinical trials.
More information can be found at http://www.xdx.com .
About AlloMap Molecular Expression Testing
The first product using this unique approach is AlloMap molecular expression testing. This service, offered through the XDx CLIA-certified clinical laboratory since January 2005, is being used by a number of leading cardiac transplant centers in the United States to monitor patients following their heart transplants. The scientific and clinical validation of this technology has been described in a peer-reviewed article published in the American Journal of Transplantation. More information can be found at http://www.allomap.com .
XDx
CONTACT: Debbie Frantz of XDx, +1-415-287-2300; or Dave Schemelia ofHealthStar Communications, for XDx, +1-646-722-8819
